What is Ogivri?
Ogivri is sometimes used when the cancer has spread to other parts of the body (metastatic).
Ogivri may also be used for purposes not listed in this medication guide.
Ogivri side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection, or in the days afterward. Tell your caregiver right away if you feel dizzy, nauseated, itchy, light-headed, weak, short of breath, or if you have a headache, fever, chills, or chest pain.
Ogivri may cause serious side effects. Call your doctor at once if you have:
new or worsening cough;
a light-headed feeling, like you might pass out;
severe headache, blurred vision, pounding in your neck or ears;
blisters or ulcers in your mouth, red or swollen gums, trouble swallowing;
heart problems--pounding heartbeats, dizziness, swelling in your lower legs, rapid weight gain, feeling short of breath;
low blood cell counts--fever, chills, tiredness, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed; or
signs of tumor cell breakdown--tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects of Ogivri may include:
nausea, diarrhea, weight loss;
trouble sleeping, feeling tired;
low blood cell counts;
fever, chills, cough, or other signs of infection;
altered sense of taste; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Do not use if you are pregnant. Use effective birth control, and tell your doctor if you become pregnant during treatment.
Some side effects may occur during the injection. Tell your caregivers if you feel dizzy, nauseated, light-headed, weak, short of breath, or if you have a headache, fever, or chills.
Before taking this medicine
Tell your doctor if you have ever had:
congestive heart failure;
a heart attack; or
any allergies or breathing problems.
You may need to have a negative pregnancy test before starting this treatment.
Do not use Ogivri if you are pregnant. Ogivri can cause injury or death to the unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 7 months after your last dose. Tell your doctor if you become pregnant.
If you become pregnant while using Ogivri or within 7 months after you stop, your name may be listed on a pregnancy registry to track the effects of trastuzumab on the baby.
It may not be safe to breastfeed while using this medicine and for up to 7 months after your last dose. Ask your doctor about any risk.
How is Ogivri given?
Your doctor will perform a medical test to make sure Ogivri is the right medicine to treat your cancer.
Ogivri is given as an infusion into a vein. A healthcare provider will give you this injection.
Ogivri is usually given once every week or every 1 to 3 weeks. Follow your doctor's dosing instructions very carefully.
This medicine must be given slowly, and the infusion can take up to 90 minutes to complete.
You may need frequent medical tests to be sure this medicine is not causing harmful effects. Your cancer treatments may be delayed based on the results.
Your heart function may need to be checked before and during treatment with Ogivri. You may also need heart function testing every 6 months for 2 years after your last dose of this medicine.
Ogivri is usually given for 52 weeks, or until your body no longer responds to the medication.
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your Ogivri.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while receiving Ogivri?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
What other drugs will affect Ogivri?
Other drugs may affect Ogivri, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Ogivri can have long lasting effects on your heart, especially if you receive other cancer medicines. For at least 7 months after your last dose of trastuzumab, tell any doctor who treats you that you have used Ogivri.
A biosimilar is a biological product that is similar to a reference biologic (usually the original product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. As an example, the biosimilar Amjevita (adalimumab-atto) was approved as the first biosimilar to Humira (adalimumab). Continue reading
The biosimilars of Herceptin are Herzuma, Kanjinti, Ogivri, Ontruzant and Trazimera Continue reading
If you are receiving Perjeta for treatment of HER2+ early breast cancer, you may continue treatments with Herceptin every 3 weeks for one year (18 cycles total). For the treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you have side effects that require you to stop treatment. You may receive other treatments with these medications. Continue reading
Treatment regimens for Herceptin vary depending on hospital protocols, but for the treatment of HER2+ early breast cancer, treatment is usually continued for one year (up to 18 cycles). Continue reading
After Herceptin treatment, your doctor will monitor you regularly for cancer progression, advise you not to become pregnant for at least 7 months (if you are of childbearing potential), and test your heart every 6 months for at least 2 years, because there is a higher risk of developing long-term heart damage in people who take Herceptin. Continue reading
T-DM1 chemotherapy refers to treatment with Kadcyla, which is a targeted treatment that may be used to treat HER2-positive breast cancer in women who meet certain criteria. The chemical name for Kadcyla is T-DM1 (also called ado-trastuzumab emtansine) and it is a combination of two medicines: trastuzumab which is a targeted treatment and DM1 which is a cytotoxic agent (also known as mertansine). Trastuzumab targets HER2-expressing breast cancer cells and delivers DM1 directly to them. Continue reading
- How many biosimilars have been approved in the United States?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
- What is a biologic drug?
More about Ogivri (trastuzumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- En español
- Ogivri (Trastuzumab Intravenous) advanced reading
- Ogivri (Trastuzumab-dkst Intravenous) (Advanced Reading)
Related treatment guides
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2023 Cerner Multum, Inc. Version: 12.04.